MR编号 | FI/H/0238/001 |
---|
药品名称 | Irinotecan Mayne 20 mg/ml |
---|
活性成分 | - irinotecan hydrochloride 20.0 mg/ml
|
---|
剂型 | Concentrate for solution for infusion |
---|
上市许可持有人 | Mayne Pharma Plc |
---|
参考成员国 - 产品名称 | Finland (FI) |
---|
互认成员国 - 产品名称 | - Denmark (DK)
Irinotecan "Mayne" - Iceland (IS)
- Ireland (IE)
- Spain (ES)
Irinotecan Rovi 20 mg/ml concentrado para solución para perfusió - Portugal (PT)
- Greece (GR)
- Norway (NO)
- Austria (AT)
Irinotecan Mayne 20 mg/ml - Konzentrat zur Herstellung einer Infusionslösung - Poland (PL)
- Latvia (LV)
Irinotecan Mayne 20 mg/ml - Hungary (HU)
Irinotecan Mayne - Cyprus (CY)
Irinotecan Hydrochloride 20 mg/ml concentrate for solution for infusion - Czechia (CZ)
Canri - Slovakia (SK)
IRINOTECAN MAYNE 20mg/ml infúzny koncentrát - Italy (IT)
|
---|
许可日期 | 2003/12/18 |
---|
最近更新日期 | 2019/01/30 |
---|
药物ATC编码 | - L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- L01 ANTINEOPLASTIC AGENTS
- L01X OTHER ANTINEOPLASTIC AGENTS
- L01XX Other antineoplastic agents
- L01XX19 irinotecan
|
---|
申请类型 | - TypeLevel1:Abridged
- TypeLevel2:Initial Application
- TypeLevel3:Generic Article 4.8(a)(iii), first paragraph
- TypeLevel4:Chemical Substance
- TypeLevel5:Prescription Only
|
---|
附件文件下载 | |
---|
市场状态 | Positive |
---|